| Diabetes Treatment and Management | Lifetime | 98 | IT 6 | 99.53 |
| Diabetes Management and Research | Lifetime | 143 | IT 9 | 99.35 |
| Angiogenesis and VEGF in Cancer | Lifetime | 110 | IT 7 | 99.17 |
| Metabolism, Diabetes, and Cancer | Lifetime | 203 | IT 14 | 99.09 |
| Peptidase Inhibition and Analysis | Lifetime | 357 | IT 13 | 98.61 |
| Adipose Tissue and Metabolism | Lifetime | 459 | IT 9 | 98.78 |
| Diet and metabolism studies | Lifetime | 644 | IT 28 | 98.88 |
| Pancreatic function and diabetes | Lifetime | 455 | IT 19 | 98.64 |
| Diabetes and associated disorders | Lifetime | 348 | IT 15 | 98.44 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 124 | IT 19 | 96.70 |
| Cardiovascular Function and Risk Factors | Lifetime | 678 | IT 43 | 98.83 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 142 | IT 7 | 97.78 |
| Pharmacology and Obesity Treatment | Lifetime | 207 | IT 18 | 97.48 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 571 | IT 21 | 98.20 |
| Lymphatic System and Diseases | Lifetime | 160 | IT 3 | 96.18 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 783 | IT 35 | 96.88 |
| Cardiovascular Health and Disease Prevention | Lifetime | 858 | IT 64 | 96.48 |
| Diet, Metabolism, and Disease | Lifetime | 887 | IT 57 | 96.23 |
| Diabetic Foot Ulcer Assessment and Management | Lifetime | 536 | IT 25 | 95.54 |
| Biomarkers in Disease Mechanisms | Lifetime | 988 | IT 120 | 78.54 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 80 | IT 5 | 97.34 |
| Diabetes Treatment and Management | 2021-2025 | 193 | IT 12 | 97.84 |
| Diabetes Management and Research | 2021-2025 | 249 | IT 17 | 96.74 |
| Pancreatic function and diabetes | 2021-2025 | 460 | IT 32 | 92.64 |
| Diabetes and associated disorders | 2021-2025 | 881 | IT 73 | 86.10 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 827 | IT 36 | 85.31 |
| Pharmacology and Obesity Treatment | 2021-2025 | 478 | IT 28 | 72.75 |
